[Fingolimod in the treatment of multiple sclerosis. Novelties presented at the annual congress of the American Academy of Neurology (Toronto, April 2010)].
Fingolimod, a sphingosine 1-phosphate receptor modulator, is currently on registration as an oral treatment for relapsing-remitting multiple sclerosis in the European Union and United States of America. New and important information on the drug was presented during the annual meeting of the American Academy of Neurology held in Toronto in April 2010, including, notably, results from the TRANSFORMS and FREEDOMS studies that, besides confirming the therapeutic benefit of the drug as a first-line therapy for multiple sclerosis, with superiority over interferon beta1a on clinical, inflammatory and functional outcomes, confirmed the safety and tolerability of the agent and described a specific benefit on the patients' functional abilities performing daily tasks. With additional new information on safety and tolerability and some new insight into the mechanism of action of fingolimod, new information presented during the meeting further supported the role of the drug in the treatment of multiple sclerosis and renewed hope for treating patients with a new therapeutic tool.